参考文献/References:
[1] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013 [J]. CA Cancer J Clin, 2013, 63(1): 11-30.
[2] Ito K, Kakehi Y, Naito S, et al. Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan[J]. Int J Urol, 2008, 15(9): 763-768.
[3] Chen X, Rycaj K, Liu X, et al. New insights into prostate cancer stem cells[J]. Cell Cycle, 2013, 12(4): 579-586.
[4] Al-Hajj M, Wicha M S, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells [J]. Proc Natl Acad Sci USA, 2003, 100(7): 3983-3988.
[5] Collins A T, Berry P A, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells [J]. Cancer Res, 2005, 65 (23):10946-10951.
[6] Antoniou A, Hebrant A, Dom G, et al. Cancer stem cells, a fuzzy evolving concept: A cell population or a cell property [J]? Cell Cycle, 2013, 12(24): 3743-3748.
[7] Patrawala L, Calhoun T, Schneider-Broussard R, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells [J]. Oncogene, 2006, 25(12): 1696-1708.
[8] Patrawala L, Calhoun-Davis T, Schneider-Broussard R, et al. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells[J]. Cancer Res, 2007, 67(14): 6796-6805.
[9] Hurt EM, Kawasaki BT, Klarmann GJ, et al. CD44+ CD24-prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis [J]. Br J Cancer, 2008, 98 (4): 756-765.
[10] Rybak AP, He L, Kapoor A, et al. Characterization of sphere-propagating cells with stem-like properties from DU145 prostate cancer cells[J]. Biochim Biophys Acta, 2011, 1813(5): 683-694.
[11] Ugolkov AV, Eisengart LJ, Luan C, et al. Expression analysis of putative stem cell markers in human benign and malignant prostate[J]. Prostate, 2011, 71(1): 18-25.
[12] Doherty RE, Haywood-Small SL, Sisley K, et al. Aldehyde dehydrogenase activity selects for the holoclone phenotype in prostate cancer cells [J]. Biochem Biophys Res Commun, 2011, 414(4):801-807.
[13] Miki J, Furusato B, Li H, et al. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens [J]. Cancer Res, 2007, 67(7):3153-3161.
[14] Van den Hoogen C, van der Horst G, Cheung H, et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer [J]. Cancer Res, 2010, 70(12): 5163-5173.
[15] Azuma M, Hirao A, Takubo K, et al. A quantitative matrigel assay for assessing repopulating capacity of prostate stem cells [J]. Biochem Biophys Res Commun, 2005, 338(2): 1164-1170.
[16] Gu G, Yuan J, Wills M, et al. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo [J]. Cancer Res, 2007, 67(10): 4807-4815.
[17] Zhang G, Ma L, Xie Y K, et al. Esophageal cancer tumorspheres involve cancer stem-like populations with elevated aldehyde dehydrogenase enzymatic activity [J]. Mol Med Rep, 2012, 6(3): 519-524.
[18] Wang ZA, Shen MM. Revisiting the concept of cancer stem cells in prostate cancer[J]. Oncogene, 2011, 30(11): 1261-1271.
[19] Wang X, Kruithof-De JM, Economides KD, et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer[J]. Nature, 2009, 461(7263): 495-500.
[20] Wang ZA, Mitrofanova A, Bergren SK, et al. Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity [J]. Nat Cell Biol, 2013, 15(3): 274-283.